Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: Correlation with CD38/CD138 expressing myeloma cells

Annals of Hematology

Volumn 82, Issue 2, 2003, Pages 88-92

  Ak, Ilknur ^a   Aslan, V ^a   Vardareli, E ^a   Gulbas Z ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Bone marrow imaging; Multiple myeloma; Tc 99m methoxyisobutylisonitrile

Indexed keywords

CD38 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PREDNISOLONE; SYNDECAN 1; VINCRISTINE; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; BIOLOGICAL MARKER; CD38 PROTEIN, HUMAN; DIAGNOSTIC AGENT; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; PROTEOGLYCAN; SDC1 PROTEIN, HUMAN; SYNDECAN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; FEMUR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ILIAC CREST; IMAGE ANALYSIS; IMAGING SYSTEM; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PELVIS; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STERNUM; THORAX; BLOOD; BONE MARROW; CANCER INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING;

ADP-RIBOSYL CYCLASE; AGED; ANTIGENS, CD; ANTIGENS, CD38; BIOLOGICAL MARKERS; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; PLASMA CELLS; PREDICTIVE VALUE OF TESTS; PROTEOGLYCANS; SEVERITY OF ILLNESS INDEX; SYNDECAN-1; SYNDECANS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0038690583     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0600-2     Document Type: Article

References (26)

1. Adams B, Fataar A, Nizami M (1996) Technetium-99m-sestamibi uptake in myeloma. J Nucl Med 37:1001-1002
2. Alexandrakis M, Kyriakou D, Passam F, Koukouraki S, Karkavitsas N (2001) Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Ann Hematol 80:349-353
3. Biassoni L, Tirovola E, Kaleva N, Kouykin V, Britton K (1995) Myeloma imaging with Tc99m-MIBI. Eur J Nucl Med 22:856
4. Catalano L, Pace L, Califano C, Pinto A, De Renzo A, Di Gennaro F, Del Vecchio S, Fonti R, Salvatore M, Rotoli B (1999) Detection of myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica 84:119-124
5. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, Pizzolo G, Menestrina F (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12:1101-1106
6. Chiu M, Kronauge J, Piwnika-Worms D (1990) Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile)-technetium (I) in cultured mouse fibroblast. J Nucl Med 31:1646-1653
7. Chun K, Cho I, Won K, Lee K, Lee H, Hyun M, Hayashida K (2001) Comparison of Tc-99m sestamibi and TI-201 uptake in multiple myeloma. Clin Nucl Med 26:212-215
8. Delmon-Moingeon L, Piwnica-Worms D, Van den Abbeele A, Holman L, Davidson A, Jones A (1990) Uptake of cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell line in vitro. Cancer Res 50:2198-2202
9. Dhodapkar M, Sanderson R (1999) Syndecan-I (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behaviour within the tumor microenvironment. Leuk Lymphoma 34:35-43
10. el-Shirbiny A, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson S (1997) Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 38:1208-1210
11. Foldes I, Levay A, Stotz G (1993) Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 20:330-333
12. Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Di Gennaro F, Catalano L, Califano C, Pace L, Rotoli B, Salvatore M (2001) Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med 28:214-220
13. Hussein M, Juturi J, Lieberman I (2002) Multiple myeloma: present and future. Curr Opin Oncol 14:31-35
14. Muller S, Guth-Tougelidis B, Creutzig H (1987) Imaging of malignant tumours with Tc-99m-MIBI SPECT (abstract). J Nucl Med 28:562
15. Pace L, Catalano L, Pinto A, De Renzo A, Di Gennaro F, Califano C, Del Vecchio S, Rotoli B, Salvatore M (1998) Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med 25:714-720
16. Pace L, Catalano L, Del Vecchio S, Di Gennaro F, De Renzo A, Sica G, Califano C, Tedesco N, Borrelli G, Rotoli B, Salvatore M (2001) Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. Eur J Nucl Med 28:304-312
17. Palmedo H, Biersack H, Lastoria S, Maublant J, Prats S, Stegner H, Bourgeois P, Hustinx R (1998) Scintimammography with technetium 99m-methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 25:375-385
18. Piwnica-Worms D, Kronauge J, Chin M (1990) Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 82:1826-1838
19. Piwnika-Worms D (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organo-technetium complex. Cancer Res 53:977-984
20. Rawstron A, Owen R, Davies F, Johnson R, Jones R, Richards S, Evans P, Child J, Smith G, Jack A, Morgan G (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 97:46-55
21. Soderlund V, Jonsson C, Bauer H, Brosjo O, Jacobsson H (1997) Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med 38:682-686
22. Svaldi M, Tappa C, Gebert U, Bettini D, Fabris PFF, Osele L, Mitterer M (2001) Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation. Ann Hematol 80:393-397
23. Tedder T, Clement L, Cooper M (1984) Discontinuous expression of a membrane antigen (HB-7) during B lymphocyte differentiation. Tissue Antigens 24:140-149
24. Tirovola E, Biassoni L, Britton K, Kaleva N, Kouykin V, Malpas J (1996) The use of 99mTc-MIBI scanning in multiple myeloma. Br J Cancer 74:1815-1820
25. Wackers F, Berman D, Maddahi J, Watson D, Beller G, Strauss H, Boucher C, Picard M, Holman B, Fridrich R (1989) Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 30:301-311
26. Yokogami K, Kawano H, Moriyama T, Uehara H, Sameshima T, Oku T, Goya T, Wakisaka S, Nagamachi S, Jinnouchi S, Tamura S (1998) Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET. Eur J Nucl Med 25:401-410